Oncology Voice Network
Join to access to all OVN content. Join for Free
Tumor-Agnostic Therapies and the Future of HER2 in Oncology
diagnostic precision oncology tumor agnostic breast cancer gastric cancer biomarker

Tumor-Agnostic Therapies and the Future of HER2 in Oncology

  • Jun 8th 2025
  • 20 mins
  • Labcorp Perspectives Oncology

Share This Article

Clips

View Media
Summary

What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types.

Tumor biology is rewriting the rules of cancer treatment.
In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs talks with Dr. Heidi Ko, Director of Medical Affairs at Labcorp and a breast medical oncologist, about the rapid evolution of tumor-agnostic therapies and HER2-targeted treatment strategies.

They unpack what these FDA approvals actually mean in clinical practice, why HER2 is becoming relevant far beyond breast and gastric cancer, and how biomarkers like ERBB2 amplification and HER2 protein expression are shaping decisions across tumor types.

Dr. Ko shares her insights from the DESTINY-PanTumor02 trial, discusses why tissue stewardship is more important than ever, and breaks down what oncologists need to know about interpreting HER2 data across IHC, FISH, and NGS.

Whether you’re navigating biomarker testing workflows or just trying to keep up with precision oncology’s fast pace, this episode offers timely context and clear clinical takeaways.

Click for Source

Related Topics

See More Topics

Meet Our Innovation Partners

You May Also Like

Article
Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer
OVN Avatar Rajat Thawani, Neha Agrawal, Nicholas F Taflin, Adel Kardosh, Emerson Y Chen

Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer

Jan 13th • 8 mins • read
Article
Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China
OVN Avatar Qiyou Wu, Zhiwei Lian, Xin Wang, Hanchao Cheng, Jing Sun, Hui Yu, Gong Zhang, Fan Wu, Jian Liu and Chuanben Chen

Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China

Jan 12th • 13 mins • read
Article
Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?
OVN Avatar Neil Carleton and Priscilla F. McAuliffe

Are the chronological age cutoffs used in clinical oncology guidelines biologically meaningful?

Dec 1st • 4 mins • read
Article
Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study
OVN Avatar Min Jeong Kim, Hyo Jung Kim, Danbee Kang, Hee Kyung Ahn, Soo-Yong Shin, Juhee Cho, Yeon Hee Park,

Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study

Oct 9th • 4 mins • read
Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Feb 23rd • 8 mins • read
Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Dec 1st • 4 mins • read

Explore OVN

Articles Expert-written insights
Browse Topics Oncology focus areas
OVN Podcast Flagship show
Community Why join OVN